We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current CALC market cap is 51.06M. The company's latest EPS is USD -3.1963 and P/E is -1.62.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -37.5M | -29.83M | -54.72M | -36.18M | -38.08M |
| Net Income | -44.09M | -34.72M | -54.6M | -35.61M | -34.36M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 40.66M | 101.79M | 69.09M | 39.67M | 12.19M |
| Total Liabilities | 12.25M | 7.01M | 4.07M | 3.7M | 4.03M |
| Total Equity | -102.95M | 94.79M | 65.02M | 35.97M | 8.16M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -31.22M | -32.06M | -31.5M | -22.88M | -25.73M |
| Investing | -20.62M | -42.56M | 10.75M | 26.96M | 8.88M |
| Financing | 54.87M | 92.17M | 695k | -139k | 20.9M |
| Market Cap | 51.06M |
| Price to Earnings Ratio | -1.62 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 10.07 |
| Price to Book Ratio | 6.83 |
| Dividend Yield | - |
| Shares Outstanding | 10.75M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.4 (8.08%) |
| Company Name | CalciMedica Inc (QB) |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.calcimedica.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
